No Data
No Data
Immunic CEO Dr Daniel Vitt on Successful 2024, With More to Come in the Year Ahead | NASDAQ:IMUX
Immunic CSO Discusses Breaking the IBD Stigma to Mark Crohn's and Colitis Awareness Week | NASDAQ:IMUX
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
Immunic's Promising Pipeline Progress and Stable Financials Justify Buy Rating
Immunic, Inc. to Participate in Investor Conference in December
Immunic Price Target Announced at $10.00/Share by HC Wainwright & Co.